MSB 4.52% 95.0¢ mesoblast limited

Elli Lilly and now Regeneron not treating advanced COIVD-19 sufferers, page-21

  1. 8,934 Posts.
    lightbulb Created with Sketch. 6773
    With all these failed treatments including convalescent blood plasma (shown by trials to have no statisticial effect), Remdesivir (see WHO), Dexamethasone (see https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30503-8/fulltext for concerns), Ibuprofren(!), hydroxychloroquine and azithromycin , Yet not a word about Mesoblast's Remi-L ??? the only one left in the race and last chance to save thousands of lives or 50-60% of covid-19 deaths , not a word out there shorts ?? what's worse is those trials were delaying our trial taking potential suitable patients that may have died in the process , the answer will drop soon enough .
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
95.0¢
Change
-0.045(4.52%)
Mkt cap ! $1.084B
Open High Low Value Volume
$1.00 $1.01 94.5¢ $2.669M 2.769M

Buyers (Bids)

No. Vol. Price($)
1 2053 95.0¢
 

Sellers (Offers)

Price($) Vol. No.
95.5¢ 13191 2
View Market Depth
Last trade - 16.10pm 20/08/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.